Brain natriuretic peptide release in cardiac surgery patients

Thoracic and Cardiovascular Surgeon

Volumn 53, Issue 3, 2005, Pages 138-143

  Sinha, Anil Martin ^a,b   Breithardt, O A ^a   Schmid, M ^a   Stellbrink, C ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b KLINIKUM COBURG   (Germany)

Author keywords

Brain natriuretic peptide; Cardiac resynchronization therapy; Cardiac surgery; Heart failure; Heart transplantation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; GLYCERYL TRINITRATE; NESIRITIDE; SPIRONOLACTONE; VALSARTAN;

AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CARDIAC GRAFT REJECTION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; HEALTH CARE COST; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; NONHUMAN; OPEN HEART SURGERY; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN SECRETION;

CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; GRAFT REJECTION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 20444441162     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-837453     Document Type: Article

References (58)

1. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81
2. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203
3. DeLemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-322
4. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328
5. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832
6. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25: 227-234
7. Tamura N, Ogawa Y, Chusho H et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. PNAS 2000; 97: 4239-4244
8. Fischer Y, Filzmaier K, Stiegler H et al. Evaluation of a new, rapid bed-side test for quantitative determination of B-type natriuretic peptide. Clin Chem 2001; 47: 591-594
9. Maisel AS, Koon J, Krishnaswamy P et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-374
10. McDonagh TA, Robb SD, Morton JJ et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13
11. Wieczorek SJ, Wu AH, Christenson R et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002; 144: 834-839
12. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601
13. Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004; 43: 416-422
14. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-982
15. McCullough PA, Due P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579
16. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600
17. McNairy M, Gardetto N, Clopton P et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 2002; 143: 406-411
18. Pfister R, Scholz M, Wielckens K et al. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6: 289-294
19. Collinson PO, Barnes SC, Gaze DC et al. Analytical performance of N terminal pro B type natriuretic peptide (NT-proBNP) assay on the ElecsysTM 1010 and 2010 analysers. Eur J Heart Fail 2004; 6: 365-368
20. Berendes E, Schmidt C, van Aken H et al. A-type and B-type natriuretic peptides in cardiac surgical procedures. Anesth Analg 2004; 98: 11-19
21. Hutfless R, Kazanegra R, Madani M et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol 2004; 43: 1873-1879
22. Wazni OM, Martin DO, Marrouche NF et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110: 124-127
23. Avidan MS, Meehan N, Ponte J, El-Gamel A, Sherwood RA. Changes in brain natriuretic peptide concentrations following open cardiac surgery with cardioplegic cardiac arrest. Clin Chim Acta 2001; 303: 127-132
24. Chello M, Mastroroberto P, Perticone F et al. Plasma levels of atrial and brain natriuretic peptides as indicators of recovery of left ventricular systolic function after coronary artery bypass. Eur J Cardiothor Surg 2001; 20: 140-146
25. Watanabe M, Egi K, Hasegawa S et al. Significance of serum atrial and brain natriuretic peptide release after coronary artery bypass grafting. Surg Today 2003; 33: 671-673
26. Bergler-Klein J, Klaar U, Heger M et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2302-2308
27. Eimer MJ, Ekery DL, Rigolin VH et al. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol 2004; 94: 676-678
28. El Gamel A, Yonan NA, Keevil B et al. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Ann Thorac Surg 1997; 63: 1095-1100
29. Chin C, Akhtar MJ, Rosenthal DN, Bernstein D. Safety and utility of the routine surveillance biopsy in pediatric patients 2 years after heart transplantation. J Pediatr 2000; 136: 238-242
30. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999; 100: 287-291
31. Claudius I, Lan YT, Chang RK, Wetzel GT, Alejos J. Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol 2003; 92: 1368-1370
32. Auricchio A, Stellbrink C, Block M et al. The effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. Circulation 1999; 99: 2993-3001
33. Breithardt OA, Sinha AM, Schwammenthal E et al. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am Coll Cardiol 2003; 41: 765-770
34. Cazeau S, Leclercq C, Lavergne T et al. Multisite stimulation in cardiomyopathies (MUSTIC) study investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-880
35. Abraham WT, Fisher WG, Smith AL et al, for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853
36. Auricchio A, Stellbrink C, Sack S et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026-2033
37. Stellbrink C, Breithardt OA, Franke A et al. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbance. J Am Coll Cardiol 2001; 38: 1957-1965
38. Sinha AM, Filzmaier K, Breithardt OA et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 2003; 91: 755-758
39. Sinha AM, Filzmaier K, Kunz D et al. Correlation of brain natriuretic peptide release, cardiopulmonary exercise testing and 6 minute walking test in patients with heart failure and cardiac resynchronization therapy. J Am Coll Cardiol 2003; 41: 60 (abstract)
40. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167
41. Maisel AS, McCord J, Nowak RM et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41: 2010-2017
42. Morrison LK, Harrison A, Krishnaswamy P et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung diseases in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-209
43. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-654
44. Goetze JP, Christoffersen C, Perko M et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB 2003; 17: 1105-1107
45. Wiviott SD, Cannon CP, Morrow DA et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 substudy. Circulation 2004; 109: 580-586
46. De Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-1021
47. Morrow DA, de Lemos JA, Sabatine MS et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41: 1264-1272
48. Richards AM, Nicholls MG, Espiner EA et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786-2792
49. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107: 2545-2547
50. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130
51. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228-1233
52. Richards AM, Doughty R, Nicholls MG et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999; 99: 786-792
53. Latini R, Masson S, Anand I et al. Effects of Valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-2458
54. Wang T, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular event and death. N Engl J Med 2004; 350: 655-663
55. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246-253
56. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin in for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-1540
57. Moazami N, Damiano RJ, Bailey MS et al. Nesiritide (BNP) in the management of postoperative cardiac patients. Ann Thorac Surg 2003; 75: 1974-1976
58. De Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure. Chest 2004; 125: 652-668